Published in Medical Letter on the CDC and FDA, March 11th, 2007
Company will file appeal for Genasense(R) NDA in CLL
Expanded Access Program to continue in U.S. during appeal
Completed response to EMEA 180-day review questions for MAA in melanoma; formal CHMP opinion expected within 90 days
Follow-on Genasense/melanoma trial initiated using key biomarker
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA